Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
217.4 USD | +4.07% | +12.46% | -15.64% |
04-26 | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
04-25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.64% | 30.42B | |
-4.06% | 86.13B | |
+1.32% | 39.82B | |
+56.59% | 25.23B | |
-14.44% | 15.36B | |
-8.82% | 11.95B | |
-15.85% | 11.6B | |
-43.00% | 11.51B | |
+6.14% | 8.71B | |
-7.02% | 8.12B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen Q1 Non-GAAP EPS, Revenue Drop; CEO Michel Vounatsos to Leave; Reaffirms 2022 Guidance